The National Institutes of Health (NIH) announced that initial Phase 1 trial results from the Moderna vaccine candidate demonstrate that the vaccine is well-tolerated and generates a strong immune response in older adults. The Phase 1 trial was expanded to enroll older adults, who are more vulnerable to COVID-19 infections and are an important population for vaccination.
The NIH notes that 40 healthy older adults ages 56 and older were enrolled in the trial and were monitored for any adverse events. The results show that the vaccine was well-tolerated, although some volunteers experienced fever and fatigue after vaccination. Additionally, the vaccine candidate generated a good immune response and developed antibodies necessary for neutralizing COVID-19 infections. The volunteers will be monitored for a year following the second does.